January 17, 2014
“The Physician’s Perspective: A health policy brief from the Institute for Patient Access,” discusses the importance of a doctor’s need to know when their patients are switched to a biosimilar –- an issue public policy makers in the states are currently considering. Read more here.
December 19, 2013
ASBM Releases New European Survey in Dublin On November 22, ASBM Executive Director Michael Reilly presented preliminary findings of a new survey on European physicians’ views on biosimilar naming at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety: 53% of physicians surveyed […]
November 22, 2013
Dublin, Ireland – The Alliance for Safe Biologic Medicines (ASBM) today released the results of a new survey on European physicians’ views on biosimilar naming. ASBM Executive Director Michael Reilly presented the findings at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety. […]
November 15, 2013
The Alliance for Patient Access (AfPA) held their National Physicians Biologics Working Group Meeting on November 15-16 in Chicago, IL where Dr. Dolinar gave the keynote address to attending physicians. In his address, Dr. Dolinar discussed the current state of biosimilars and explained the disconnect between the science and potential policies and how they will impact […]
November 7, 2013
InsideHealthPolicy’s FDA Week an exclusive weekly report on Food and Drug Administration policy, regulation and enforcement From Vol. 19, No. 44, November 1, 2013 BIO Disagrees With Lawmakers, Says ACA Left Biosimilar Naming To FDA The innovator biologics industry disagrees with a bipartisan group of senators’ view that FDA would violate congressional intent if it […]
October 28, 2013
The Alliance for Safe Biologic Medicines (ASBM) executive director, Michael Reilly, was featured in a Globe & Mail video series on biosimilars. Mr. Reilly provides a global perspective on biosimilars, with a focus on why manufacturing matters. Globe & Mail is the national newspaper for Canada and this new online series will provide viewers with […]
October 22, 2013
ASBM Presents at WHO Meeting on Naming in Geneva Calls for Distinct Non-Proprietary Names to Ensure Patient Safety Geneva, Switzerland – The Alliance for Safe Biologic Medicines (ASBM) today presented at the World Health Organization’s (WHO) 57th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances in Geneva, Switzerland. During his presentation, ASBM Chairman, Richard […]
October 22, 2013
On Oct 22, 2013, Andrew Spiegel, Executive Director of the Global Colon Cancer Association, testified in support of biosimilar legislation under consideration in IN. Indiana Health Finance Commission-GCCA Testimony
October 10, 2013
Dolinar Letter to the Editor Published by GaBI in Advance of WHO Naming Meeting On September 27th, a Letter to the Editor by ASBM Chairman Richard Dolinar, M.D. was featured in the Generics and Biosimilars Initiative Journal (GaBI). The piece commends the World Health Organization (WHO) for its attention to an upcoming action on the […]
October 10, 2013
Re: Support of HB 746-Biosimilars Thank you for providing this opportunity to speak about this important issue. My name is Andrew Spiegel. I am the Executive Director of the Global Colon Cancer Alliance. The Global Colon Cancer Alliance (GCCA) is the voice for colon cancer patients worldwide. Before running the GCCA, I was CEO and […]
